Treatment of Thrombotic Antiphospholipid Syndrome : The Rationale of Current Management - An Insight into Future Approaches by C.B. Chighizola et al.
Review Article
Treatment of Thrombotic Antiphospholipid Syndrome:
The Rationale of Current Management—An Insight into
Future Approaches
Cecilia Beatrice Chighizola,1,2 Tania Ubiali,2,3 and Pier Luigi Meroni1,2,3
1 Immunology Research Laboratory, IRCCS Istituto Auxologico Italiano, Via Zucchi 18, 20095 Cusano Milanino, Italy
2Department of Clinical Sciences and Community Health, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy
3Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Piazza Cardinal Ferrari 1, 20122 Milan, Italy
Correspondence should be addressed to Pier Luigi Meroni; pierluigi.meroni@unimi.it
Received 24 December 2014; Accepted 15 April 2015
Academic Editor: Mahboobeh Mahdavinia
Copyright © 2015 Cecilia Beatrice Chighizola et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Vascular thrombosis and pregnancy morbidity represent the clinical manifestations of antiphospholipid syndrome (APS), which is
serologically characterized by the persistent positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents
currently provide the mainstay of APS treatment. However, the debate is still open: controversies involve the intensity and the
duration of anticoagulation and the treatment of stroke and refractory cases. Unfortunately, the literature cannot provide definite
answers to these controversial issues as it is flawed by many limitations, mainly due to the recruitment of patients not fulfilling
laboratory and clinical criteria for APS.The recommended therapeutic management of different aPL-related clinical manifestations
is hereby presented, with a critical appraisal of the evidence supporting such approaches. Cutting edge therapeutic strategies are
also discussed, presenting the pioneer reports about the efficacy of novel pharmacological agents in APS. Thanks to a better
understanding of aPL pathogenic mechanisms, new therapeutic targets will soon be explored. Much work is still to be done to
unravel the most controversial issues about APS management: future studies are warranted to define the optimal management
according to aPL risk profile and to assess the impact of a strict control of cardiovascular risk factors on disease control.
1. Introduction
Antiphospholipid syndrome (APS) is an autoimmune dis-
order characterized by vascular thrombosis and/or preg-
nancy morbidity in the persistent presence of circulating
antiphospholipid antibodies (aPL). Antibodies against 𝛽2-
glycoprotein I (anti-𝛽2GPI antibodies) and cardiolipin (aCL),
together with the functional assay lupus anticoagulant (LA),
are the three laboratory tests considered in the revised criteria
for the diagnosis of the syndrome. Persistent medium/high
positivity, confirmed 12 weeks apart, of at least one of these
tests is necessary to diagnose APS [1].
In a large multicentre European cohort of 1000 APS
patients, deep vein thrombosis emerged as the most frequent
presentingmanifestation, and other common vascular events
were stroke and pulmonary embolism [2]. The catastrophic
variant of APS (CAPS) is a serious aPL-related manifes-
tation, occurring in less than 1% of cases. Multiple small-
vessel thrombotic events manifest concomitantly at different
anatomic sites in association with a systemic inflammatory
response syndrome, which is secondary to the abundant
release of cytokines from necrotic tissues [3].
aPL-related vascular events exert a strong clinical impact
in terms of morbidity and mortality: it has been estimated
that APS affects at least 1% of the general population [2].
In addition, this chronic and disabling condition usually
presents in early adulthood: the median age at disease
onset is 31 years [4]. Such epidemiological evidence implies
that APS diagnosis carries high social and economic
costs, making pivotal to correctly manage these patients.
The optimal therapeutic approach to APS should aim at
attenuating the procoagulant state balancing the side effects
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of anticoagulation: a careful weighting of risks and benefits
should be performed, taking into account the hazard of
recurrence as well as of bleeding.
The evaluation of the pros/cons ratio for each treatment
option acquires particular importance when evaluating the
primary thromboprophylaxis of aPL carriers. In this context,
the aPL profile should be carefully considered, taking into
account that low-titre and transient aPL positivity does not
display a clinical significance, being described even in healthy
individuals and in several pathological conditions, such as
infections.
On the other hand, anticoagulation is burdened by
significant side effects: such poor safety profile of drugs acting
on the coagulation cascade explains why novel therapeu-
tic approaches are currently under investigation, in order
to identify pharmacological tools specifically counteracting
aPL-mediated prothrombotic effects.
2. aPL Pathogenic Mechanisms
aPL do not provide merely serum APS biomarkers but rather
exert a direct pathogenic role in both vascular and obstetric
events. aPL are a heterogeneous family of autoantibodies
reacting against proteins with affinity for negatively charged
phospholipids (PL). In particular, 𝛽2-glycoprotein I (𝛽2GPI)
provides, together with prothrombin, the main epitope tar-
geted by aPL. Three configurations of 𝛽2GPI have been
described: circulating plasma 𝛽2GPI exists in a circular form;
upon binding to suitable anionic surfaces as cardiolipin (CL)
and other PL or to LPS, the molecule opens into a J-shaped
fish-hook configuration. 𝛽2GPI consists of 5 domains (D):
DI–IV comprise 60 amino acids and contain two disulfide
bridges each, while DV is aberrant, as it includes 82 amino
acids due to a 6-residue insertion and a 19-residue C-
terminal extension cross-linked by an additional disulfide
bond. DI has been identified as the most relevant antigenic
target involved in 𝛽2GPI/anti-𝛽2GPI antibody binding. This
epitope is a cryptic and conformation-dependent structure:
in the circular conformation of 𝛽2GPI, DI interacts with DV
and the critical epitope is thus hidden. Several factors might
lead to the surface exposition of the critical epitope, such as
oxidative stress. Indeed, under oxidative conditions, disulfide
bonds form in the molecule leading to the unmasking of the
critical B-cell structure [5].
aPL are well accepted to exert a thrombogenic effects
in vitro; aPL mediate such a thrombophilic state by inter-
fering with both soluble components and cells involved in
the coagulation cascade [6]. aPL promote aggregation and
activation of platelets, neutralizing 𝛽2GPI interaction with
von Willebrand factor and enhancing the expression of
platelet membrane glycoprotein (GP) IIb/IIIa. Moreover, aPL
induce a proinflammatory and procoagulant endothelial phe-
notype upregulating cellular adhesion molecules, promoting
the synthesis of endothelial nitric oxide synthase (eNOS)
and of proinflammatory cytokines as interleukin (IL)-6 and
tumour necrosis factor- (TNF-) 𝛼. aPL-induced effects on
the endothelium are mainly mediated by the reactivity of the
autoantibodies with 𝛽2GPI expressed on the endothelial cell
(EC) membrane. Many molecules have been advocated as
potential mediators of 𝛽2GPI interaction with ECs: Annexin
A2, Toll-like receptor (TLR) 2 and 4, Heparan-sulfate,
and ApoER2’. Lastly, aPL have been shown to significantly
increase in both ECs and monocytes the expression of tissue
factor (TF), the major initiator of the clotting cascade. There
is general agreement that nuclear factor 𝜅B (NF𝜅B) and p38
mitogen-activated protein kinase (p38MAPK) are involved in
the downstream signalling pathways engaged by aPL in EC
andmonocyte activation. In addition, aPL have been recently
demonstrated to recruit the mammalian target of rapamycin
(mTOR) via the phosphatidylinositol 3-kinase- (PI3K-) AKT
pathway [7]. However, aPL are not sufficient per se to trigger
thrombosis in vivo: clotting takes place exclusively in the
presence of a second hit (“two-hit hypothesis”) [6].
3. The Impact of aPL-Related Vascular
Events in the Real Life
3.1. Frequency of Thrombotic APS. In a recent work by the
APS ACTION, the systematic analysis of 73 relevant papers
allowed estimating the aPL positivity rate in the general
population with related vascular outcomes as follows: 10%
in patients with deep vein thrombosis, 11% in subjects
myocardial infarction, and 14% in individuals with stroke [8].
3.2. The Strength of Association of aPL with Vascular Events.
According to a recent literature revision, the association with
aPL appears to be rather solid for vascular events: 54% of
studies confirmed the association of aPL with deep venous
thrombosis, 55% the association with myocardial infarction,
and 71% the association with stroke [9].
4. Risk Stratification
aPL carriers do not display all a similar thrombotic hazard;
several parameters should be accounted to accurately stratify
the risk of developing a vascular event.
4.1. aPL Profile. Each aPL profile confers a characteristic
thrombotic risk. Among the three criteria aPL test, LA has
been appointed as the strongest predictor of clinical events,
raising the risk of thrombosis by approximately 4-fold [8, 10].
The thrombotic risk increases with the number of positive
aPL tests, with triple positive patients displaying the highest
vascular hazard. According to the revised classification cri-
teria, APS patients might be stratified into four categories
upon the number of positive aPL tests: category I includes
patients with more than one positive test in any combination,
while patients with a single positive test should be classified
in category II [1]. aPL isotypes should also be considered:
IgG are clinically more meaningful compared to IgM [11].
Recently, an increasing interest has been catalysed by IgA
isotype, whose role in APS warrants further investigation.
Among the novel diagnostic and prognostic tool, the subset
of anti-𝛽2GPI autoantibodies specifically reacting against DI
displays a higher specificity for APS and predicts thrombosis
[3].
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4.2. Associated Autoimmune Conditions. Patients with an
underlying systemic autoimmune condition present an excess
vascular morbidity, not fully ascribable to traditional cardio-
vascular risk factors. In particular, aPL positivity has been
identified as one of the main determinants of thrombosis
among subjects with systemic lupus erythematosus (SLE)
[12].
4.3. Cardiovascular Risk Factors. The two-hit hypothesis fits
well with the clinical observation that thrombotic events
occur only occasionally despite the persistent presence of
aPL. Consistently, most APS patients experiencing a throm-
botic event present concomitant cardiovascular risk factors.
In particular, hypertension has emerged as an independent
predictor for a first thrombotic event in aPL carriers [11].
Infections have also been found to precede APS onset, and
their frequency can be as high as 24% in CAPS patients
[13]. Consequently, a careful assessment of cardiovascular
status should be accomplished in all aPL-positive individuals:
age, diabetes, arterial hypertension, dyslipidemia, obesity,
smoking, sedentary lifestyle, hyperhomocysteinemia, Protein
C, Protein S, and ATIII deficiency, Factor V Leyden and
prothrombin mutations, prolonged immobilization, surgical
procedures, and oestrogen use.
4.4. Site of Thrombosis. Historically, patients with a first
arterial event were regarded at higher risk of experiencing a
recurrence, with recurrent event almost invariably involving
the same circulatory district [14]. This belief is mainly
supported by the only survey analysing arterial and venous
events separately, concluding that the risk of recurrence was
higher for arterial than venous events [15]. Accordingly, two
cohort studies reported a higher incidence of arterial events
compared to venous ones: 56 versus 51 recurrences in the
EuroAPS cohort (even though venous eventswere twicemore
frequent as APS presenting manifestations [2]) and 14 versus
5 in the Singapore cohort [16]. In addition, a case-control
study identified previous arterial thrombosis, together with
smoking and diabetes, as a predictor of new arterial events
[17]. Conversely, in a cohort of high-risk subjects the event at
presentation did not predict the site of the recurrence [18].
5. Therapeutic Management of Thrombotic
APS Manifestations
Some issues in the pharmacological management of throm-
botic APS are still subject of a vigorous debate. These criti-
cisms are difficult to solve because of the several limitations
flawing the whole literature, including the two randomized
studies assessing the efficacy of anticoagulation [19, 20].
Critical items relate to the following issues:
(a) Study Design. Most studies present (i) a retrospective
design and (ii) a small sample size.
(b) aPL Testing. Many studies have included patients
not fulfilling APS laboratory criteria in terms of (i)
number of aPL tests performed; (ii) aPL positivity
confirmation; (iii) aPL cut-off.
(c) Patients’ Selection. Recruited patients were not strat-
ified upon (i) aPL profile; (ii) cardiovascular risk
factors; and (iii) site of thrombosis (arterial versus
venous).
To overcome these issues and highlight evidence, two system-
atic reviews included treatment recommendations for aPL-
related thrombotic events [21, 22], while an international Task
Force elaborated a consensus document on the primary and
secondary thromboprophylaxis in individuals carrying aPL
[23].
5.1. Pharmacological Agents. The mainstay of the treatment
of thrombotic APS is provided by agents that counteract aPL-
mediated effects by preventing coagulation.
Antiplatelets as low-dose aspirin (LDASA) aremore effec-
tive in preventing arterial thrombosis: in the high-flow, high-
shear arterial circulation platelet adhesion and aggregation
play a major role.
Anticoagulant drugs include vitamin K antagonists
(VKA), heparin, and its derivatives.
VKAs act by inhibiting the process of gamma-glutamyl
carboxylation of factors II, VII, IX, and X, as well as Protein
C and Protein S. The most commonly used VKAs are 4-
hydroxycoumarins; among these, warfarin is the most fre-
quently prescribed. VKA treatment presents several pitfalls.
These agents have a slow onset of action and a narrow ther-
apeutic window and necessitate frequent INR monitoring.
Indeed, they interact with a number of foods and drugs
including immunosuppressive agents as azathioprine; VKA
activitymay fluctuatewith alcohol consumption, intercurrent
illness, exercise, and smoking. In aPL carriers, VKAmonitor-
ingmay be rather troublesomebecause of the variable respon-
siveness of thromboplastins to LA, even though amulticentre
study concluded that LA interference did not significantly
affect PT-INRmeasured with most of commercially available
thromboplastins. On the other hand, LA detection in patients
on VKA is impaired, thus limiting APS diagnosis among
these subjects [24].
Native heparin is a natural anticoagulant whose structure
consists of a variable sulfated repeating disaccharide unit,
with a molecular weight ranging from 3 to 30 kDa. The inac-
tivation of thrombin by heparin requires at least 18 saccharide
units, while the action on factor Xa necessitates only of
heparin’s pentasaccharide binding site. Interestingly, heparin’s
activity in APS is not merely attributable to its anticoagulant
action. Heparin directly interacts with 𝛽2GPI: the primary
heparin-binding site is located on the second positively
charged site within DV of 𝛽2GPI protein, the domain also
deputized to PL binding. Heparin greatly enhanced the
plasmin-mediated cleavage of Lys317-Thr318 site in 𝛽2GPI,
resulting in a diminished ability of𝛽2GPI to recognize PL and
the consequent impairment of the prothrombotic activity of
anti-𝛽2GPI antibodies [25].
Heparin derivatives as low molecular weight heparin
(LMWH) present a lower molecular weight, with the conse-
quent loss of the action on thrombin and a better therapeutic
index. At variance to warfarin, these derivatives have no
food/alcohol interactions and few drug interactions and do
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not require routine monitoring thanks to the predictable
dose-response relationship. Limitations of LMWH are its
subcutaneous administration and side effects as heparin-
induced thrombocytopenia (HIT) and osteoporosis.
5.2. Bleeding Risk. The risk of bleeding has been shown
to progressively increase with the rising of anticoagulation
intensity, though this is a nonlinear association. Estimates
of the bleeding risk in APS patients are derived from stud-
ies evaluating treatment efficacy. A 2007 systematic review
evaluating eight studies reported an overall major bleeding
rate between 0.57 and 10% per year [22]. However, when
considering only recent studies where target INR was 2.0-
3.0, the annual bleeding rate dropped down to 0.8–1.6%
[26]. Interestingly, the single study specifically addressing the
risk of bleeding in APS patients reported no fatal bleeding
episodes, and precipitating factors were identified in all cases
[27]. It is crucial to note that in APS patients the mortality
rate due to thrombosis is higher than the mortality rate
due to bleeding. A systematic review considering studies
published up to 2007 documented 18 deaths due to recurrent
thrombosis, comparedwith only one decease being attributed
to haemorrhage [22]. Most recently, 27 of 1000 patients
included in the EuroAPS cohort died during the follow-up
period as a consequence of thrombosis, with haemorrhage
being the cause of death in only 6 patients [17].
To note, INRfluctuations increasewith higher intensity of
anticoagulation, contributing to the instauration of not only a
hemorrhagic status but also a thrombogenic profile. It is thus
crucial to estimate the individual risk of bleeding, in order
to prevent complications and improve the quality of life of
patients. Independent predictors of major bleeding include
INR values above 4.0, concomitant treatment with aspirin,
age over 75 years, polypharmacy, history of gastrointesti-
nal tract bleeding, malignancy, lack of education regarding
anticoagulation therapy, and leukoaraiosis. In APS patients,
uncontrolled blood pressure has also been associated with
an increased risk of bleeding. Consequently, special caution
should be paid when considering high-intensity anticoagula-
tion or combined aspirin and warfarin therapy.
5.3. Venous Thrombotic Events. Starting treatment of venous
thrombosis in APS patients follows the recommendations
for the management of thrombotic events in the general
population: initial therapy consists of UFH or LMWH for
at least five days, embraced with anticoagulant agents [28].
With regard to long-term management of patients with
venous thrombosis, the optimal intensity and duration of
anticoagulation are still matter of debate.
5.3.1. Intensity of Anticoagulation. The management of
patients with venous thrombosis envisages two options about
anticoagulation intensity:moderate (INR 2.0-3.0) versus high
(3.0-4.0) intensity.
(i) Moderate-Intensity Anticoagulation. The effectiveness of
moderate-intensity anticoagulation is supported by some
lines of evidences.
(a) Standard anticoagulation at a target INR below 3.0
appeared to confer effective protection against venous
recurrences [13, 29–32]. However, it should be noted
that many of the above cited studies have recruited
patients presenting laboratory tests not fulfilling cri-
teria for full-blown APS.
(b) The two randomized clinical studies comparing
moderate- and high-intensity anticoagulation in
patients with a definite APS diagnosis failed to
report any difference between the two regimens [19,
33]. Both studies had been specifically designed to
demonstrate that high-intensity warfarin offered a
better prevention of recurrent thrombosis compared
to moderate-intensity anticoagulation. In the study
by Crowther on 114 APS patients, the incidence
of recurrent thrombosis was even higher among
patients receiving high-intensity warfarin (10.7%)
compared to those in the moderate-intensity arm
(3.4%), although this difference did not achieve
statistical significance [19]. Conversely, in the 2005
WASP trial, the recurrence incidences were 11.1% and
5.5% among patients receiving moderate-intensity
and high-intensity warfarin respectively [20]. To note,
both studies present limited statistical power, because
of the inadequate sample size. Another strong bias
potentially affected result interpretation: patients in
the high-intensity group presented an INR below
the target range for over 40% of the follow-up
time thus limiting the interpretation of the efficacy
of high-intensity regimen. On the other hand, this
observation suggests that patients experience more
difficulties in keeping INR in the high-intensity range,
which may account for the increased frequency of
thrombotic recurrences described with the high-
intensity regimen in one study. Furthermore, only
18% of patients in the Canadian study and 55% in the
WAPS trial had a high-risk aPL profile.
(c) Not surprisingly, a meta-analysis combining the
results of the two randomized studies using Peto’s
method could not demonstrate any difference in the
rate of thrombosis recurrence between the two reg-
imens, although an almost significant excess throm-
botic risk was observed with high-intensity anticoag-
ulation [20]. The effectiveness of standard anticoagu-
lation was also supported by a 2007 systematic review
by Ruiz-Irastorza considering randomized as well as
observational studies [19–22, 29].
(ii) High-Intensity Anticoagulation. Some retrospective stud-
ies suggested that high-intensity regimen was more effective
in preventing thrombotic recurrence compared to either
LDASA or low-intensity anticoagulation among unselected
APS patients [33, 34] and those with a history of venous
thrombosis [35].
More recently, a 45% recurrence ratewas observed among
triple-positive APS patients with a previous venous events
receiving standard anticoagulant therapy over a 6-year period
reflecting the poor protection offered by standard-intensity
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warfarin therapy against recurrent events in this high-risk
group [18].
5.3.2. Duration of Anticoagulation. There is currently general
consensus to prescribe indefinite anticoagulation to APS
patients with a history of venous thrombosis [23]. Neverthe-
less, an increasing debate has emerged about the potential
withdrawal of anticoagulation in a definite subset of aPL
patients.
(i) Indefinite Anticoagulation. The choice of indefinite anti-
coagulation for APS patients is supported by the evidence
that these patients carry a higher risk of recurrent thrombosis
compared to aPL negative subjects, and such thrombotic
risk actually increases with time [14]. The persistency of
aCL positivity 6 months after a venous event was found to
predict thrombotic recurrence and death, with its predictive
value increasing with higher titres [32]. In particular, the
risk of recurrence was demonstrated to be highest in the
six months following discontinuation of anticoagulant drugs
[34]. Consistently, cessation of warfarin was shown to induce
a thrombotic phenotype because of the recovery of normal
levels of procoagulant factors, in turn leading to a stronger
interaction between TF and factor VII [36].
(ii) Three-Month Anticoagulation. In a randomized trial
comparing one-month to three-month anticoagulation in
patients with venous thrombosis and a transient reversible
risk factor, subgroup analysis showed that aPL positivity
tested at the time of randomization did not predict venous
recurrence [28]. Consistently, over the recent years two-
case series demonstrated safe termination of anticoagulation
amongAPS patients who eventually became aPL negative [37,
38]. In this subset of patients, aPL may not play a pathogenic
role but rather constitutes an epiphenomenon. It has been
therefore proposed that APS patients with a first venous
event and a low-risk aPL profile plus a known transient
precipitating risk factor could be candidate for 3- to 6-
month anticoagulation. In this context, it is advisable to assess
ultrasonographically the residual thrombosis and to test D-
dimer before suspension of anticoagulation therapy. In the
general population, the presence of residual vein thrombosis
has been shown to increase the risk of recurrences by 50%,
while a negative D-dimer result onemonth after anticoagula-
tion withdrawal reduces the risk of recurrent thrombosis by
twofold. However, the role of ultrasonography and D-dimer
test has not yet been assessed in APS population.
5.4. Arterial Thrombotic Events. There is overall consensus
that APS patients with a previous arterial event deserve
indefinite anticoagulation; the optimal intensity of the anti-
coagulant regimen is still debated.
5.4.1. Moderate-Intensity Anticoagulation. The randomized
trials by Crowther and Finazzi recruited also patients with
a history of arterial events, even though the latter were
underrepresented compared to subjects experiencing venous
thrombosis (24% in the study by Crowther and 32% in
the trial promoted by Finazzi). As previously pointed out,
these two studies were not in support of a superiority of high
intensity as compared to moderate-intensity anticoagulation
[19, 20]. Consequently, a 2006 systematic review including
only these randomized controlled trials recommended mod-
erate anticoagulation [21].
5.4.2. High-Intensity Anticoagulation. The requirement of
high-intensity anticoagulation is suggested by the observa-
tion that in many studies oral anticoagulation to a standard
target INR range of 2.0 to 3.0 was not sufficient in preventing
recurrences among patients presenting with arterial events
[4, 14, 33, 34, 39, 40].
Consistently, most new thrombotic events occur with an
INR below 3.0, as suggested by several cohort studies [11–13,
33, 39, 40] and one randomized controlled study [19, 27, 41].
The choice of a high-intensity regimen is further sup-
ported by the higher recurrence risk experienced by APS
patients with a history of arterial events, as suggested in some,
but not all, studies [2, 15–18]. Indeed, a 47% recurrence rate
was observed in a cohort of triple-positive APS patients with
a previous arterial thrombosis receiving standard anticoagu-
lation, suggesting its incomplete efficacy [18].
5.5. Stroke. Thrombotic events in APS commonly involve
the cerebral circulation; stroke is the presenting clinical
manifestation in 13% of cases while 7% of APS patients
develop a transient ischemic attack at disease presentation.
In a large European cohort, stroke accounted for 13% of
deaths, at a mean age of 42 years [4]. In case of cerebral
arterial thrombosis, the therapeutic scenario also comprises
antiplatelet agents.
5.5.1. Low-Dose Aspirin. In the randomized controlled Anti-
phospholipid Antibodies and Stroke Study (APASS), aspirin
at a dose of 325mg daily was shown to be as effective as
low-intensity anticoagulation in the secondary prevention
of stroke among aPL-positive patients [42]. However, the
APASS study is flawed by some limitations: aPL positivity
was not confirmed 12 weeks apart; patients were recruited
even when aCL positivity was detected at low-titres. These
biases preclude results’ extrapolation to patients with definite
APS. Indeed, those subjects with baseline positivity for both
LA and aCL tended to have a higher event rate (31.7%) than
subjects who tested negative for both antibodies (24%).
5.5.2. Low-Dose Aspirin Plus Moderate-Intensity Anticoagu-
lation. In 2009, Okuma first shed light on the combination
of LDASA with moderate-intensity anticoagulation as a
therapeutic option in stroke patients with a definite diagnosis
of APS. In his randomized controlled trial, a lower incidence
of recurrent stroke was observed among patients treated with
LDASA plus warfarin compared to those receiving LDASA
alone, with a cumulative stroke-free survival of 74% versus
25%. However, this study is flawed by important limitations:
firstly, the sample size was rather small, no details about aPL
profiles of included patients were provided, and limited data
on stroke recurrences in each group were available [43].
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Given this conflicting picture, an international Task Force
could not reach a consensus about the optimal management
of arterial thrombosis. Eight out of the 13members of the Task
Force suggested treatment with warfarin with INR over 3.0
for patients with definite APS; the combination of moderate
anticoagulation and aspirin was also listed as an option, while
LDASAwas reserved to stroke patients with a low-risk profile
and reversible thrombotic risk factors [23].
Details of the studies addressing therapeutic regimens in
thrombotic APS are enlisted in Table 1.
6. Additional Therapeutic Tools
Few pharmacological agents have been investigated as alter-
natives to warfarin; several others have been proposed as
adjunctive tools.
6.1. Hydroxychloroquine. Hydroxychloroquine (HCQ) is an
antimalarial drug with anti-inflammatory and antithrom-
botic properties. In addition, HCQ has been shown to exert
immunomodulatory effects: it prevents activation of TLR3,
TLR7, and TLR9, inhibits antigen processing and presen-
tation, and reduces circulating immune complexes [55]. In
in vitro models of thrombotic APS, HCQ has been demon-
strated to inhibit GPIIb/IIIa expression on aPL-activated
platelets [56], to reverse the formation of aPL-𝛽2GPI-PL
bilayer complexes [57] and to prevent the aPL-induced dis-
ruption of the Annexin A5 shield [58]. Its antithrombogenic
properties have been confirmed in in vivo models of APS:
HCQ injection in mice induced a dose-dependent decrease
in thrombus size [59].
In primary thrombotic APS, HCQ has been evaluated
as an adjunctive pharmacological tool: patients receiving a
combo regimen comprising HCQ plus oral anticoagulation
experienced less recurrences compared to those on antico-
agulants only. However, the extrapolation of data is affected
by the limitations biasing this work: the study cohort was
limited to 40 patients, and the follow-up lasted 36 months
only [60]. Nevertheless, HCQ is currently catalysing much
attention in APS: an ongoing study is assessing the effect
of HCQ on Annexin A5 resistance assay in aPL patients
with or without SLE; a randomized controlled trial promoted
by the international research organization APS ACTION is
evaluating HCQ in the primary prevention of thrombosis in
aPL asymptomatic carriers at five-year follow-up [61].
Even though there is limited clinical evidence of its
antithrombotic effects in primary APS, treatment guidelines
consider HCQ as a potential adjunctive therapy, particularly
in consideration of its excellent safety profile [23].
6.2. Novel Anticoagulants. Fondaparinux is a synthetic pen-
tasaccharide homologous to heparin binding site; its activity
is limited on factor Xa. Fondaparinux has been licensed for
thromboprophylaxis, but it has not been yet evaluated in the
setting of APS.
Most recently, a novel class of anticoagulants has been
synthesized: all are administered orally; these pharmacologi-
cal agents inhibit a single enzyme of the coagulation cascade,
being thus called direct oral anticoagulants (DOA). Dabi-
gatran is a potent, competitive, reversible direct thrombin
inhibitor, which binds to thrombin and blocks its interaction
with substrates. Direct FXa inhibitors include rivaroxaban,
apixaban, and edoxaban. All these agents are highly selective,
reversible, competitive, and dose-dependent. They represent
an advance over VKA mainly in terms of a better quality of
life for patients: since they display a predictable anticoagulant
effect, DOA are administered at a fixed dose. In addition,
being not metabolized by the cytochrome P450 system, they
do not interact with dietary constituents or alcohol and
have few reported drug interactions, therefore not requiring
routinemonitoring of anticoagulant intensity.However, these
novel DOA do not allow overcoming some other limitations
affecting treatment with VKA. The main issue lies in the sig-
nificant bleeding risk that any anticoagulant regimen carries,
in the absence of an available pharmacological reversal agent
[62].
Dabigatran and rivaroxaban have been prescribed to a
cohort of 24 French APS patients (11 and 13, resp.); over
a median follow-up of 15 months, a single recurrent event
was registered [63]. In a UK cohort of 18 APS subjects,
rivaroxaban was proved to be safe over 12.9 months [64].
However, caution should be paid when prescribing DOA to
APS patients: recently, three cases of thrombotic recurrence
upon switching from warfarin to rivaroxaban have been
presented [65].
The role of these emerging anticoagulants in APS man-
agement is still to be clearly determined: there are few
on-going randomized controlled clinical trials evaluating
rivaroxaban in the management of APS, as compared to low
intensity anticoagulation.The RAPS trial has been promoted
by a UK group; it is a phase II/III study that has recruited
156 APS patients with a history of venous thromboembolism.
A Spanish phase III trial has been started in Spain on 218
patients with venous or arterial events. Most recently, an
Italian trial considering triple positive APS patients only is
going to start recruiting [62].
6.3. Statins. Statins inhibit cholesterol synthesis in themeval-
onate pathway by blocking the 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase. The use of statins
in the treatment of APS might thus be beneficial in the
prevention of thrombosis since hypertriglyceridemia and low
HDL cholesterol levels provide the most frequent cardiovas-
cular risk factor reported in APS patients [66]. However,
these pharmacological compounds have also been shown to
exert a wide array of additional pleiotropic antithrombotic
and anti-inflammatory effects in APS. In vitro, fluvastatin,
simvastatin, and rosuvastatin have been demonstrated to
inhibit TF synthesis in EC [67]; fluvastatin and simvastatin
were both reported to suppress anti-𝛽2GPI antibody-induced
endothelial adhesiveness and to reducemonocyte adhesion to
the endothelium [68] while rosuvastatin inhibited the upreg-
ulation of VCAM induced by aPL [69]. In vivo, fluvastatin
reduced the size of the thrombus induced by aPL infusion
and the leukocyte adhesion to EC. These findings have been
later confirmed in ex vivo studies. A trial in 42 patients with
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Table 2: Details of clinical studies investigating efficacy of long-term treatment with LMWH in resistant thrombotic APS.
Author, year [Ref] Type of study 𝑁 patients Inclusion criteria Treatments Observationtime
Recurrence
Rate
Bick and Rice, 1999
[45] Retrospective 24
APS patients resistant or
intolerant to warfarin Dalteparin 309 days 0
Ahmed et al., 2002
[46] Case-report 1
APS patient with
difficulties in keeping
INR in target
Enoxaparin 1.5mg/kg
daily 90 days
1 (pulmonary
TE)
Dentali et al., 2005
[47] Case-report 2
APS patients refractory
to warfarin
Enoxaparin 10000 IU td
Dalteparin 10000U td
2 years
6 years 0
Vargas-Hitos et al.,
2011 [48] Retrospective 23
APS patients refractory
to warfarin Enoxaparin 36 months 0.13
APS treated with fluvastatin for 30 days reported a decline
in several thrombogenic and inflammatory mediators in
monocytes [70]. More recently, Erkan observed a significant
reduction of half of the evaluated proinflammatory and
procoagulant parameters (IL1𝛽, VEGF, TNF𝛼, IP10, CD40L,
and TF) in a cohort of 41 aPL asymptomatic carriers after
three months of treatment with fluvastatin [71].
6.4. Vitamin D. In vitro, vitamin D exerts an antithrombotic
and immunomodulator function by inhibiting anti-𝛽2GPI
antibody-mediated TF expression [72]. Retrospective studies
indicated that the prevalence of vitamin D deficiency in APS
patients ranges from 10 to 50%, while insufficiencymay occur
in up to 70% of patients [8, 72–75]. Low vitamin D levels
correlate with arterial and venous thrombosis as well as with
noncriteria APSmanifestations [72, 73, 76]. Conversely, most
studies supported no association between low vitamin D
levels and obstetric APS [72–74, 76].
6.5. Sirolimus. Sirolimus, an mTOR inhibitor, has been used
in patients with APS nephropathy undergoing kidney trans-
plantation. Patients receiving sirolimus in the posttransplant
immunosuppressant regimen developed no vascular lesion
recurrence. Compared to those in the standard regimen
arm, patients on sirolimus had a higher rate of functioning
allograft at 144 months (70% versus 11%) and a decreased
vascular proliferation on biopsy [7].
7. Refractory Thrombotic APS
A significant rate of APS patients develops recurrent events
despite adequate treatment. In past prospective studies, the
yearly incidence of recurrent events among APS subjects
receiving antithrombotic therapy ranged between 3 and 24%
[29, 30, 58], with this rate even increasing up to 52–69% in
retrospective studies [31, 32]. Recurrences yield an impor-
tant mortality; unfortunately, univocal recommendations to
manage these situations are still warranted. Firstly, it should
be assessed whether the thrombotic event occurred at a sub-
therapeutic INR range. If the INR is found to be lower than
the target, it can be considered to continue with a moderate-
intensity regimen, keeping the INR in the therapeutic range.
Additional therapeutic strategies include the following.
7.1. High-Intensity Anticoagulation. If the INR was within
the therapeutic range at the time of the recurrence, one
option consists in increasing the intensity of anticoagulation.
Notably, there is no current evidence in support of this
strategy, as both randomized clinical studies by Crowther and
Finazzi excluded patients who had a thrombosis while taking
warfarin, thus preventing any conclusion about the efficacy of
high-intensity anticoagulation in this setting [19, 20].
7.2. Low-Dose Aspirin. In patients with arterial events, a
potential option is provided by the addition of LDASA to
anticoagulant treatment. However, it should be considered
that this combination is burdened by a higher bleeding risk.
Moreover, very limited evidence is available: only a small,
low-quality randomized controlled trial has shown that
combination therapy was more effective than aspirin alone in
the secondary prevention of aPL-related stroke [43].
7.3. Dual Antiplatelet Treatment. Dual antiplatelet treatment
(different combination of LDASA, ticlopidine, clopidogrel,
and cilostazol) has been recently proposed: a Japanese study
on 82 APS patients with refractory arterial events docu-
mented no recurrences among those subjects receiving dual
antiplatelet agents [44].
7.4. Low Molecular Weight Heparin. According to the evi-
dence-based consensus guideline formulated at the 13th
International Congress on Antiphospholipid Antibodies,
long-term LMWH may also be considered as a safe and
effective alternative to warfarin. Details of the reports in
support of this therapeutic option in APS are listed in Table 2
[45–48, 77]. Consistently, the 2003 CLOT study stated that
dalteparin was even more effective than warfarin in reducing
the risk of recurrent embolic events among cancer patients
[77].
7.5. Intravenous Immunoglobulins. In vivo and in vitro
models suggest the therapeutic potential of intravenous
immunoglobulins (IVIg) in APS. IVIg were shown to inhibit
aPL, by partially neutralizing LA activity and preventing aCL
binding toCLbyFab. IVIg exert an anti-idiotype activity, with
inactivation of idiotype-bearing B-cell clones. Furthermore,
Journal of Immunology Research 11
IVIg have been demonstrated to increase IgG catabolism,
to modulate complement activation, to block Fc𝛾 recep-
tor on macrophages, and to downregulate proinflammatory
cytokines [78]. Treatment with IVIg resulted in an inhibition
of aPL thrombogenic effects, with a reduction of circulating
aCL levels [79]. There are few reports about successful treat-
ment with IVIg in the management of aPL-related clinical
manifestations, mainly haematological (thrombocytopenia,
haemolytic anaemia, and hypoprothrombinemia). Treatment
response was observed in all cases with a single exception
[80]. Recently, IVIg were found to be effective in preventing
thrombosis in 7 patients in addition to conventional therapy
[81], as well as in a cohort of 5 patients with refractory APS in
a five-year open study [82].
7.6. Anti-B-Cell Agents. The pivotal role exerted by B cells in
APS has been progressively deciphered: B lymphocytes con-
tribute toAPS etiopathogenesis by producing autoantibodies,
inducing the formation of germinal centres and the synthesis
of cytokines. Accordingly, in NZW x BXSB mice, treatment
with IgG against B-cell activating factor (BAFF) receptor did
not prevent the development of aCL even though it prevented
aPL-related thrombotic vasculopathy, prolonging survival
[83]. In the same murine models, IgG against cytotoxic T-
lymphocyte antigen 4 immunoglobulin (CTLA4) affected
initiation but not development of APS. These data suggest
the potential efficacy of belimumab and abatacept in APS
[84]. Interestingly, in belimumab-treated patients with SLE
a positive-to-negative conversion rate was reported for aCL
[85]. To date, clinical experience of B-cell inhibitory agents
in APS patients is restricted to the use of rituximab, a
chimericmonoclonal antibody targetingCD20 on the surface
of B cells. Successful treatment with rituximab has been
reported in anecdotal reports and in one case series from
the BIOGEAS registry. In this multicentre Spanish registry,
a therapeutic response was observed in 92% of 12 cases [86].
In 2012, a review collected all the published cases, identifying
27 APS patients treated with rituximab [87]. The anti-CD20
monoclonal resulted in a decrease of aPL titres; among those
receiving rituximab because of thrombotic recurrences, clin-
ical improvement was observed in all cases. Moreover, ritux-
imabwas beneficial for a plethora of aPL-related clinicalman-
ifestations. In this regard, an open-label phase IIa descriptive
pilot study (RITAPS) has been carried out in 20 patients with
noncriteria APS manifestations refractory to conventional
treatments [88]. Rituximab resulted to be effective in control-
ling some but not all noncriteriamanifestations, without sub-
stantial change in aPL profile. Notably, caution should be paid
to its use in APS: episodes of severe acute thrombotic exac-
erbations (lacunar infarctions and transverse myelitis) have
been reported in two APS/SLE patients receiving rituximab
[89].
8. Catastrophic APS
Although CAPS is a rare event, the high mortality rate makes
this a clinically relevant issue [4]. Most of the available
evidence comes from the CAPS registry, a web-based
international registry of CAPS patients created by the
European Forum on anti-phospholipid antibodies.
8.1. Combination Therapy. In CAPS registry, the most effec-
tive therapeutic approach comprised anticoagulation, cor-
ticosteroids, and plasma exchange; this combination was
indeed associated with the highest recovery rate (77.8%).
Anticoagulation, corticosteroids, plasma exchange, and/or
IVIg induced a recovery in 69% of cases. While there was no
difference between these two combinations, a trend towards
statistical significance was observed between each of these
regimens compared to all the remaining options (77.8%
versus 55.4%, 𝑝 = 0.083 and 69% versus 54.4%, 𝑝 = 0.089).
Isolated use of steroids was related to a lower rate of recovery
(18.2% versus 58.1% of episodes not treated with corticos-
teroids;𝑝 = 0.01) [90]. Plasma exchange is specially indicated
when schistocytes are present and should be initiated within
12 hours from the onset [91].
In refractory CAPS, the available evidence comes from
anecdotal reports concerning the use of second-line agents
as rituximab, eculizumab, and defibrotide.
8.2. Rituximab. Rituximab has been used in 20 cases of
CAPS, in different combination with anticoagulation, high
doses of steroids, plasma exchange, and IVIg. Despite the
difficulties in determining the effects of rituximab, a lower
mortality compared to larger series emerged [92].
8.3. Eculizumab. The complement system, in particular the
mediator C5a, has been shown to play a central role in APS.
C5a, a potent anaphylatoxic, proinflammatory, and chemo-
tactic molecule, was demonstrated to induce the expression
of TF on ECs [93] and neutrophils [94]. In vivo, C5a was
involved in deposition of fibrin in a growing thrombus
induced by aPL injection [95]. Eculizumab is a humanized
monoclonal antibody which binds to the C5 protein with
high affinity, thereby inhibiting its cleavage to C5a and
C5b thus preventing the generation of membrane attack
complex [96]. To date, eculizumab has been administered
to few CAPS patients in whom all the other therapeutic
strategies proved to be ineffective. A favourable response was
described in two cases [97, 98] and a negative outcome in
the others [61]. Eculizumab has also been investigated as a
tool to manage APS patients after renal transplantation. In
a first report on three consecutive kidney transplant recipi-
ents with posttransplant aPL-mediated thrombotic microan-
giopathy (TMA) resistant to plasmapheresis, treatment with
eculizumab improved TMA [99]. In another case series of
three patients treated with anticoagulation and eculizumab,
no systemic thrombotic events or early graft losses were
reported after a follow-up ranging from 4 months to 4 years
[100].
8.4. Defibrotide. Defibrotide is a polydispersemixture of 90%
single-stranded and 10% double-stranded phosphodiester
oligonucleotides derived from the controlled depolymeri-
sation of porcine intestinal mucosal DNA. This pharma-
cological compound acts by upregulating the release of
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prostacyclin and prostaglandin E2, reducing concentrations
of leukotriene B4, inhibiting monocyte superoxide anion
generation, stimulating expression of thrombomodulin in
human vascular ECs, and modulating platelet activity [101].
More recently, defibrotide was shown to downregulate TF
expression on monocytes [102]. To date, it has been used
in two patients with CAPS: in one case this treatment was
successful, while the second patient died [103, 104].
9. aPL Asymptomatic Carriers
All the studies exploring the thrombotic risk among aPL car-
riers described a rather low annual rate, around 1% patient-
years (range 0–2.8%) [105]. A recent systematic review con-
cluded that this subgroup of patients presents a recurrence
rate comparable to aPL negative individuals. This explains
why many studies addressing this issue failed to report a
clear protective effect for primary prophylaxis and accounts
for the evidence that life-long anticoagulation should not be
prescribed to those patients not fulfilling laboratory criteria
for APS diagnosis.
9.1. Low Molecular Weight Heparin. Evidence-based guide-
lines recommendations strongly advised to administer
LMWH thromboprophylaxis to cover high-risk situations
such as trauma, infections, surgery, and prolonged immobi-
lization: this was suggested by a 3-year prospective cohort
study [41]. Forty-six–seventy-six percent of vascular events in
aPL subjects occur concomitantly with other prothrombotic
risk factor [11], strongly highlighting the importance of a
prompt correction of thrombotic risk factors [23].
9.2. Low-Dose Aspirin. A recent meta-analysis showed a
decrease in the risk of thrombotic events by LDASA among
asymptomatic aPL carriers, SLE patients, and women with
obstetrical APS. Noteworthy, such risk reduction did not
maintain statistical significance when prospective studies or
those with the best methodological quality were considered
[106]. Indeed, the only randomized controlled trial included
in this meta-analysis, the APLASA study, reported that
LDASAwas not more effective than placebo for primary pro-
phylaxis of thrombotic events [53]. Consequently, evidence-
based guidelines do not recommend universal thrombo-
prophylaxis with LDASA to asymptomatic aPL individuals
[23].
Most recently, a randomized controlled trial examining
the efficacy of LDASA versus LDASA plus low-intensity anti-
coagulation as primary thrombotic prevention (ALIWAPAS)
was published. In an overall cohort of 166 asymptomatic
carriers, the two arms presented the same rate of thrombosis
during the 5 years of follow-up, with more bleeding episodes
in the LDASA plus warfarin group. These data make the
combo therapy not acceptable as a treatment option for these
patients [54].
The scenario changes drastically when considering
patients with an underlying autoimmune disease. Indeed,
there is a growing bulk of evidence that autoimmune diseases
represent a thrombotic risk factor per se: the inflammation
peculiar of these pathologic conditions directly contributes
to the accelerated atherosclerosis and the significant cardio-
vascular mortality observed in these patients [107]. Conse-
quently, given the higher thrombotic rate (around 3.7–4%)
reported in this population [12, 51, 52, 108, 109], primary
prophylactic treatment is recommended among patients with
aPL and an associated autoimmune disease [23]. In this
setting, LDASA is the drug most commonly prescribed. The
efficacy of LDASA in the primary intervention of aPL positive
SLE patients has been investigated in three studies, one
retrospective and two prospective, all showing a beneficial
effect on thrombosis [12, 108, 109]. In 2000, Wahl and
colleagues used aMarkov decision analysis model to evaluate
the prophylactic role of LDASA in aPL-positive SLE patients,
suggesting that it was effective in reducing the number of
thrombotic events. In particular, LDASA induced a benefit
outweighing the treatment-associated risk of major bleeding
[110].
9.3. Hydroxychloroquine. An increasing number of experts
propose HCQ as primary prophylaxis. Clinical data on the
effectiveness of HCQ in preventing aPL-related thrombotic
events have been derived from studies in SLE cohorts. Two
retrospective studies concordantly showed that the protective
effects played by HCQ against thrombosis [111, 112]; a cross-
sectional study on 77 APS patients and 56 asymptomatic aPL
carriers from a SLE registry proved that the probability of a
thrombotic event was decreased by LDASA or HCQ use [50].
In a still unpublished work, Law and coworkers observed
a decrease in arterial as well as venous thrombosis in aPL-
positive lupus patients receiving HCQ [113]. Accordingly,
a systematic review concluded that antimalarials exert an
antithrombotic action among SLE patients [114].
Details of the studies investigating management of aPL
asymptomatic carriers are listed in Table 3.
10. Potential Future Therapeutic Target
To date, management strategies in APS have been mainly
restricted to anticoagulation, which is not effective in all
patients. Hopefully, the unravelling of APS pathogenicmech-
anisms may allow identifying alternative therapeutic targets.
10.1. Novel Molecules Blocking 𝛽2/Anti-𝛽2GPI Antibody
Binding. (i) TIFI is a 20-amino acid synthetic peptide
that spans Thr101–Thr120 of ULB0-HCMVA from human
cytomegalovirus, which shares similarities with the PL-
binding site in 𝛽2GPI molecule, DV. TIFI is not targeted by
aPL; in vitro evidence suggests that TIFI inhibits the binding
of labelled 𝛽2GPI to human ECs andmouse monocytes [115].
These findings were also confirmed in animal models: the
infusion of this synthetic peptide inhibited aPL-mediated
thrombosis by decreasing the thrombus size produced in
response to aPL and by reducing the binding of fluores-
ceinated 𝛽2GPI to ECs [116].
(ii) Accordingly, a synthetic 𝛽2GPI-DI was shown to
inhibit aPL-mediated prothrombic effects both in vivo and in
vitro [117].
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(iii) MBB2 is a novel single chain variable fragment-
(scFv-) Fc monoclonal antibody targeting DI of human, rat,
and mouse 𝛽2GPI. When infused to experimental animals,
MBB2 caused blood clots in rat mesenteric microcircula-
tion after LPS priming. A noncomplement-fixing variant of
MBB2, MBB2ΔCH2, has also been developed. MBB2ΔCH2
displays the same antigen specificity ofMBB2 but, lacking the
CH2 domain, is unable to activate the complement cascade.
MBB2ΔCH2 has been shown to prevent the aPL-coagulant
effects in vivo by competing with circulating aPL for binding
to 𝛽2GPI. In vivo, the CH2-deleted monoclonal antibody
significantly reduced mesenteric thrombus formation and
vessel occlusion [118].
(iv) It can also be postulated that antagonists of the recep-
tors involved in 𝛽2GPI cell binding may exert a therapeutic
potential [119]. The use of antagonists or neutralizing mon-
oclonal antibodies acting on TLR2/4 might be speculated
in APS. In addition, DV of 𝛽2GPI binds the A1 ligand-
binding type A module of ApoER2󸀠, a dimer composed of
two A1 molecules joined by a flexible linker, has been shown
to inhibit anti-𝛽2GPI antibody/dimerized 𝛽2GPI immune
complexes from binding negatively charged PL and ApoER2󸀠
in vitro, more potently than A1 in the monomeric form [120].
More recently, proofs of the effectiveness of this dimeric
molecule were obtained in vivo, in two animalmodels of APS.
Indeed, treatment with A1-A1 efficiently reduced thrombus
size in vivo in the presence of chronic autoimmune anti-
𝛽2GPI antibody in lupus-prone (NZW3BXSB)F1 male mice
as well as in wild-type mice after infusion with anti-𝛽2GPI
antibodies [121].
(v) Similarly, blockers of the intracellular mediators
involved in aPL-activated signalling pathways may reverse
the prothrombotic phenotype: NF𝜅B and p38MAPK
inhibitors have been shown to be effective in preventing aPL
mediated prothrombotic and proinflammatory effects in
vitro [122]. More recently, the NF𝜅B inhibitor DHMEQ was
demonstrated to ameliorate the prothrombotic state induced
by the infusion of the monoclonal antibody WB-6 in normal
BALB/c mice [123].
10.2. Novel Molecules Interfering with aPL-Induced Mediators.
(i) It can be speculated that TF inhibitionmay prevent throm-
bosis in APS [124]. Currently, there are few drugs available on
the market blocking TF expression: ACE inhibitors, dilazep,
defibrotide, and dipyridamole. In particular, both dilazep and
dipyridamole have been shown to block the upregulation of
TF specifically induced by polyclonal IgG purified from APS
patients in monocytes [125, 126]. However, their role in APS
management has been scarcely documented.
(ii) aPL also upregulate GPIIb/IIIa thus leading to platelet
aggregation. Abciximab is a specific GPIIb/IIIa inhibitor
routinely prescribed in stroke and acute coronary syndromes,
which might be beneficial in APS [127].
(iii) Protein disulphide isomerase is the enzyme responsi-
ble for the formation of two disulphide bridges within 𝛽2GPI
molecule, a reaction leading to an oxidized and immunogenic
molecule.This enzyme is inhibited by quercetin-3-rutinoside,
whose potential pharmacological effect in APS has to be
investigated. In animal models, inhibitors of PDI were effec-
tive in treating thrombosis [128].
(iv) Given that oxidation leads to the unmasking of
the critical B-cell epitope, it might be worth exploring the
role of antioxidant compounds as N-acetylcysteine, vitamin
C, and coenzyme Q10 in APS [120]. In an in vitro study,
the inhibition of intracellular reactive oxygen species in
monocytes prevented the upregulation of TF induced by aPL
[129].
(v) Similarly, TNF-𝛼 and IL-6 are proinflammatorymedi-
ators induced by aPL: it is therefore reasonable to hypothesize
that the blockade of these cytokines with biologic agents may
be clinically beneficial [122].
The mechanisms of action of the potential future thera-
peutic tools in APS management are detailed in Figure 1.
11. Conclusions
Antiplatelet and anticoagulant agents still provide the cor-
nerstone of APS treatment, even though many clinical issues
remain still unresolved. Hopefully, these critical issues will
be soon overcome thanks to large, multicentre clinical trials.
A well-designed study should account for the relative contri-
bution of the different clinical variables: APS manifestations
may be indeed highly diverse, being related to aPL profile as
well as to the concomitant cardiovascular risk factors.
For the time being, an evidence-based approachwould be
the following (Figure 2):
(i) patients with venous events should receive long-term
anticoagulation at an INR target of 2.0-3.0;
(ii) patients with a history of arterial thrombosis should
receive long-term anticoagulation at an INR target of
2.0-3.0;
(iii) subjects who develop a stroke and present a low-
risk aPL profile without any associated autoimmune
condition may be prescribed with LDASA;
(iv) stroke patients at higher thrombotic risk and indi-
viduals with a history of arterial thrombosis should
receive long term anticoagulation;
(v) a primary thromboprophylaxis with LDASA should
be instituted in asymptomatic carrierswith a clinically
significant aPL profile or additional thrombotic risk
factors; HCQ should be prescribed to subjects with
underlying autoimmune diseases.
In addition, a strict management of prothrombotic risk fac-
tors is warranted in all aPL carriers; unfortunately, no study
has yet addressed the potential effects of controlling cardio-
vascular status on outcome. Similarly, the pleiotropic effects
of agents such as statins andHCQ should be further assessed:
the addition of these drugs to standard anticoagulation may
lead to a better disease control.Moreover, the identification of
novel diagnostic tools, such as antibodies against DI of𝛽2GPI
or against phosphatidylserine/prothrombin, may allow more
precise risk stratification, leading to a tailored treatment
strategy. Research has been galvanized to identify novel
therapeutic targets: hopefully, such pharmacological agents
might revolutionize APS management in the near future.
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